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Introduction
Lung cancer is the leading cause of cancer death world-
wide. It is also the most common cause of cancer death
in women and the second most common cause in men
in Taiwan.1 A majority of patients with non-small cell
lung cancer (NSCLC) are diagnosed with advanced
disease. Surgical resection is the treatment of choice for
patients with early-stage NSCLC.2 The 5-year survival
of patients with resected stage I NSCLC ranges from
55% to 80%.2–5
Lung cancer screening programs have shown that
the stage distribution of lung cancer at diagnosis has
shifted to earlier stages, therefore, the possibility of cure
has increased.6,7 Although the risk of death from lung
cancer has not significantly reduced,6,7 these results
have led to enthusiasm for early detection of small-size
lung cancer. With the wide use of high-resolution com-
puted tomography (CT) for screening in asymptom-
atic individuals, NSCLC with a diameter of ≤ 1 cm 
is detected more frequently. Long-term survival rate
and patterns of tumor recurrence in these patients have
not been well documented in the literature. The opti-
mal extent of pulmonary resection for NSCLC ≤ 1 cm
remains controversial.8–14 Although there is no lung
cancer screening program in Taiwan, more lung
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tumors with a diameter of ≤ 1 cm have been detected
incidentally due to widespread use of high-resolution
CT in recent physical examinations.
In this study, we investigated the surgical outcomes
and analyzed the prognostic factors in patients with
resected NSCLC ≤ 1 cm in diameter.
Methods
From January 1982 to December 2007, we retrospec-
tively reviewed all patients who underwent surgical
resection for NSCLC with a diameter of ≤ 1 cm in
Taipei Veterans General Hospital. Patients who had
neoadjuvant therapy before surgery were excluded. 
A total of 71 patients were enrolled. Preoperative stag-
ing work-up included complete blood count, serum
biochemistry tests, chest CT scan, bronchoscopic
examination, and whole body bone scintigraphy.
Mediastinoscopy was not a routine procedure in the
preoperative staging work-up unless there were en-
larged lymph nodes (diameter > 1.0 cm). Mediastinal
lymph node dissection or sampling was undertaken in
the majority of patients. All resected specimens were
examined for pathological staging. Histological typ-
ing was determined according to the World Health
Organization classification.15 The disease stages were
determined according to the TNM Classification of
Malignant Tumours of the American Joint Committee
for Cancer Staging and Revised International System
for Staging Lung Cancer.3,16
To investigate their impact on overall survival, the
following clinicopathological factors were used in uni-
variate and multivariate analyses: age (≤ 60 vs. > 60
years); sex (female vs. male); symptoms (absent vs. pres-
ent); smoking index (≤ 20 vs. > 20 pack-years); location
(right vs. left lung); tumor size (< 1 vs. 1 cm); histo-
logical type (squamous cell carcinoma vs. others);
pathological stage (IA vs. IB); extent of pulmonary
resection (standard vs. sublobar resection); and num-
ber of lymph nodes dissected (≤ 15 vs. > 15). Standard
resection was defined as lobectomy or pulmonary
resection larger than lobectomy. Operative mortality
was defined as death during the same hospitalization
or within the first 30 days after the operation. Local
recurrence was defined as tumor recurrence in the
ipsilateral hemithorax and mediastinum. Distant me-
tastasis was defined as tumor recurrence in the con-
tralateral lung or outside the hemithorax after surgical
resection. The length of overall survival was defined as
the interval in months between the date of surgical re-
section and the date of either death or the last follow-up.
All the patients were followed up at our outpatient
department at intervals of 3 months in the first 2 years
after resection, and intervals of 6 months thereafter.
The overall survival was calculated by the Kaplan–
Meier method.17 The χ2 test was used to compare be-
tween groups. Univariate and multivariate analyses were
performed by means of the Cox proportional hazards
model using SPSS version 16.0 (SPSS Inc., Chicago,
IL, USA). Only variables with p < 0.1 after univariate
analysis were entered into multivariate analysis. A 
p value < 0.05 was considered significant.
Results
The median follow-up time for the 71 patients was
33.3 months (range, 0.2–254.6 months). The number
of patients with NSCLC ≤ 1 cm diameter increased
gradually over the study period. The numbers of pa-
tients in the first decade, second decade and final 6
years of the study period were 14, 19 and 38, respec-
tively. Sixteen patients (22.5%) were diagnosed before
surgical intervention. The clinicopathological charac-
teristics of all patients are listed in Table 1. Pathological
stage was IA in 55 patients, IB in 13, IIIA in 1, IIIB
in 1, and IV in 1. Sixty-eight patients (95.8%) had
stage I disease. Complete resection was performed in
these 68 patients. The other 3 patients underwent
non-curative resection due to pleural seeding in 2 and
encased mediastinal lymph node in 1. There was 1
operative death (1.4%) caused by acute myocardial in-
farction on postoperative day 5 after complete resec-
tion with pneumonectomy for a tumor located in the
main bronchus. Postoperative complications occurred
in 13 patients (18.3%), and no patient required re-
operation during the postoperative period (Table 2).
At the last follow-up session, 46 (64.8%) patients were
alive (including 1 with recurrent cancer and 2 with non-
curative resection). Eighteen patients (25.4%) died of
other causes without tumor recurrence, and 6 (8.5%)
died of lung cancer.
We excluded the 3 patients who underwent non-
curative resection from prognostic analysis of survival.
The characteristics of the remaining 68 patients are
listed in Table 1. The median follow-up time was
33.8 months (range, 0.2–254.6 months). Only 3 of
the 68 patients received adjuvant therapy. The 5- and
10-year overall survival rates were 81.7% and 44.9%,
respectively (Figure 1). The pathological stage was IA
(80.9%) or IB (19.1%). Sublobar resection was per-
formed in 14 patients (20.6%), with 10 of them due to
poor pulmonary reserve and the other 4 due to comor-
bidity. There were 10 patients who underwent sublo-
bar resection and received lymph node dissection.
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The mean number of lymph nodes in the 10 patients
was 20.1 ± 10.9.
Six (8.8%) of the 68 patients who underwent com-
plete resection had tumor recurrence during follow-up
(Table 3). Three patients had local recurrence, whereas
the other 3 developed distant metastases. Five (9.3%)
of 54 patients who underwent standard resection
developed tumor recurrence, whereas only 1 (7.1%) of
14 patients treated by sublobar resection had recur-
rent disease. The difference was not statistically signif-
icant (p = 0.569).
Univariate analysis indicated that sex (p = 0.024),
smoking index (p=0.008), histological type (p=0.021),
extent of pulmonary resection (p = 0.045), and num-
ber of lymph nodes dissected (p = 0.038) significantly
influenced overall survival (Table 4). The overall sur-
vival was significantly worse in male patients, and in
those with higher smoking index, squamous cell carci-
noma, or who underwent sublobar resection. Sublobar
resection was a significant predictor for worse survival
(hazard ratio, 5.00; 95% confidence interval, 1.28–
20.00; p = 0.020) in multivariate analysis (Table 5).
Discussion
This study investigated the prognostic factors and
patterns of recurrence in resected NSCLC ≤ 1 cm in
diameter. Most patients (approximately 96%) with
Table 1. Clinicopathological characteristics of 71 patients with
non-small cell lung cancer with a diameter ≤ 1 cm*
All patients
Patients with 
complete 
resection 
Variables
(n = 71)
(n = 68)
Age (yr) 63.9 ± 11.5 63.4 ± 11.4
Sex
Male 44 (62.0) 43 (63.2)
Female 27 (38.0) 25 (36.8)
Symptoms
Absent 41 (57.7) 38 (55.9)
Present 30 (42.3) 30 (44.1)
Smoking index 22.8 ± 27.9 23.0 ± 27.9
(pack-years)
Tumor location
Right lung 44 (62.0) 43 (63.2)
Left lung 27 (38.0) 25 (36.8)
Tumor size (cm) 0.9 ± 0.1 0.9 ± 0.1
< 1 25 (35.2) 23 (33.8)
1 46 (64.8) 45 (66.2)
Histological type
Adenocarcinoma 45 (63.4) 43 (63.2)
Squamous cell carcinoma 20 (28.2) 20 (29.4)
Bronchoalveolar carcinoma 5 (7.0) 4 (5.9)
Large cell carcinoma 1 (1.4) 1 (1.5)
Pathologic stage
T1N0M0 - IA 55 (77.5) 55 (80.9)
T2N0M0 - IB 13 (18.3) 13 (19.1)
T2N2M0 - IIIA 1 (1.4) 0 (0.0)
T4N0M0 - IIIB 1 (1.4) 0 (0.0)
T4N0M1 - IV 1 (1.4) 0 (0.0)
Extent of pulmonary resection
Sublobar resection 16 (22.5) 14 (20.6)
Lobectomy 48 (67.6) 47 (69.1)
Bilobectomy 4 (5.6) 4 (5.9)
Pneumonectomy 3 (4.2) 3 (4.4)
No. of LNs dissected 16.5 ± 10.9 17.0 ± 10.8
≤ 15 35 (49.3) 32 (47.1)
> 15 36 (50.7) 36 (52.9)
Residual tumor
No 68 (95.8) 68 (100.0)
Yes 3 (4.2) 0 (0.0)
*Data presented as mean ± standard deviation or n (%). LN = lymph node.
Figure 1. Overall survival of 68 patients who underwent complete
resection for non-small cell lung cancer ≤ 1 cm in diameter.
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Table 2. Postoperative complications in 71 patients with non-
small cell lung cancer with a diameter ≤ 1 cm
Variables Patients (n)
Acute myocardial infarction 1
Prolonged air leak > 7 d 4
Persistent pleural drainage > 7 d 3
Empyema 1
Chylothorax 1
Deep vein thrombosis 1
Hoarseness 1
Gastrointestinal bleeding 1
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NSCLC ≤ 1 cm in diameter had stage I disease. The
5-year overall survival rate after complete resection was
81.7%. Sublobar resection was a significant prognos-
tic indicator for worse overall survival in multivariate
analysis.
Tumor size is a well-established prognostic factor
in NSCLC.3 Some studies have shown improved sur-
vival for stage I NSCLC with diameter ≤ 2 cm,13,18–20
whereas others have not.21,22 The survival and prog-
nostic factors in NSCLC ≤ 1 cm in diameter have not
been well elucidated. The frequency of stage I disease
in patients with NSCLC ≤1cm in diameter ranges from
86% to 100%.8,23,24 Although Lee and colleagues24
reported a 5-year overall survival rate of 86% in patients
with resected NSCLC of diameter ≤ 1 cm, Miller and
coworkers8 found only 64% in their series. Kondo and
colleagues23 showed that the 5-year overall survival rate
in patients with peripheral lung adenocarcinoma ≤ 1 cm
in diameter was 97.3%. They also indicated that pa-
tients with subcentimeter lung adenocarcinomas had
significantly better prognosis than those with adeno-
carcinomas between 1 and 2 cm.23 In our study, 96% of
patients with NSCLC ≤ 1 cm in diameter had stage I
disease. The 5-year overall survival rate was 81.7%,
which is between those reported in the literature.
The relationship between tumor size and regional
lymph node involvement has been reported. The preva-
lence of pulmonary hilar and mediastinal lymph nodes
metastases increases with tumor size.25,26 Some authors
have reported that there is no lymph node metastasis
in NSCLC with a diameter of ≤ 1 cm.23,26–28 Miller
and coworkers8 reported that 7% of patients with
NSCLC with a diameter ≤1cm had nodal involvement.
Table 4. Univariate analysis for overall survival in 68 patients
who underwent complete resection for non-small cell lung
cancer ≤ 1 cm in diameter
Variables Hazard ratio* (95% CI) p
Age (≤ 60 vs. > 60 yr) 2.19 (0.90–5.35) 0.084
Sex (female vs. male) 4.07 (1.20–13.74) 0.024
Symptoms (absent 1.23 (1.36–3.30) 0.490
vs. present)
Smoking index (≤ 20 3.48 (1.38–8.85) 0.008
vs. > 20 pack-years)
Location (right 0.99 (0.44–2.25) 0.993
vs. left lung)
Tumor size 1.03 (0.40–2.64) 0.955
(< 1 vs. 1 cm)
Histological type 0.37 (0.16–0.86) 0.021
(squamous cell 
carcinoma vs. others)
Pathologic stage 0.76 (0.25–2.29) 0.629
(IA vs. IB)
Extent of pulmonary 3.79 (1.03–13.89) 0.045
resection (standard 
vs. sublobar resection)
No. of LNs dissected 0.37 (0.14–0.95) 0.038
(≤ 15 vs. > 15)
*Hazard ratio was based on average mortality of the second category of
each variable compared with the baseline category. CI = confidence interval;
LN = lymph node.
Table 5. Multivariate analysis for overall survival in 68 patients
who underwent complete resection for non-small cell lung
cancer ≤ 1 cm in diameter
Variables Hazard ratio* (95% CI) p
Age (≤ 60 vs. > 60 yr) 1.39 (0.54–3.53) 0.492
Sex (female vs. male) 1.03 (0.18–5.73) 0.976
Smoking index (≤ 20 2.45 (0.68–8.85) 0.172
vs. > 20 pack-years)
Histological type 0.48 (0.18–1.27) 0.138
(squamous cell 
carcinoma vs. others)
Extent of pulmonary 5.00 (1.28–20.00) 0.020
resection (standard 
vs. sublobar resection)
No. of LNs dissected 0.75 (0.26–2.16) 0.588
(≤ 15 vs. > 15)
*Hazard ratio was based on average mortality of the second category of
each variable compared with the baseline category. CI = confidence interval;
LN = lymph node.
Table 3. Patterns of recurrence in 68 patients after complete resection
No.
Pathological 
Operation Recurrence Sites of recurrence
Disease-free Post-recurrence 
Final status
stage interval (mo) survival (mo)
1 IA Wedge resection Local Margin and mediastinal LNs 3.2 14.6 Dead
2 IA Lobectomy Distant Contralateral lung 20.3 9.2 Alive
3 IA Lobectomy Distant Bone 12.4 42.8 Dead
4 IB Bilobectomy Local Margin 9.9 26.3 Dead
5 IB Lobectomy Local Mediastinal LNs 103.1* 3.5 Dead
6 IB Lobectomy Distant Bone 18.4 6.0 Dead
*This patient was lost to follow-up 1 year after surgery and presented with hoarseness due to mediastinal lymph node recurrence 8 years later. LN = lymph node.
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Lee and colleagues24 reported a similar result of 7.2%.
In our study, lymph node metastasis was found in only
1 patient (1.4%). However, pleural spreading was dis-
covered in another 2 patients during surgical explo-
ration. These 3 patients (4.2%) had unexpectedly
advanced disease and complete (R0) resection could
not be achieved.
There can still be tumor recurrence in subcenti-
meter lung cancers after complete resection. Miller
and coworkers8 reported that the overall incidence of
recurrence in patients with resected stage I NSCLC
with a diameter ≤ 1 cm was 18%. They also reported a
55% greater risk of tumor recurrence after sublobar
resection compared with lobectomy for NSCLC ≤ 1 cm
in size. Lee and colleagues24 demonstrated that over-
all incidence of recurrence in patients with resected
NSCLC ≤ 1 cm was 6.0%, but no recurrence was found
in patients with stage IA disease. Our study showed
that tumor recurrence was found in 6 patients (8.8%)
after complete surgical resection, including 3 with local
recurrence and 3 with distant metastasis. Although
complete surgical resection offers a chance to cure the
disease, tumor recurrence can take place after surgery.
Therefore, regular follow-up is necessary after complete
resection in patients with lung cancers < 1 cm in size.
The role of sublobar resection in early-stage
NSCLC remains controversial. Complete anatomical
resection, including pneumonectomy, bilobectomy and
lobectomy, with radical lymph node dissection remains
the standard treatment for patients with early-stage
NSCLC.9 Sublobar resection is associated with a sig-
nificant increase in local recurrence, compared with
lobectomy.10,11 However, there is increasing evidence
in the literature to suggest that segmentectomy is 
an alternative to lobectomy in patients with clinical
T1N0M0 tumors ≤ 2 cm in diameter.12–14 Lee et al24
reported that there was no difference in overall sur-
vival between patients with limited resection and those
with complete anatomical resection for NSCLC ≤ 1 cm
in diameter. No recurrence was found in either the
limited resection or the complete anatomical resec-
tion group during follow-up in that study. Miller and
colleagues8 demonstrated that patients who undergo
lobectomy for NSCLC that measures ≤ 1 cm have sig-
nificantly improved survival and less recurrence than
those treated with sublobar resection. In our study, the
extent of pulmonary resection was a significant predic-
tor for overall survival in multivariate analysis. Patients
with standard resection had better overall survival than
those with sublobar resection. One patient in the
sublobar resection group had local recurrence during
follow-up. In the lobectomy group, 1 local recurrence
and 3 distant metastases were discovered. Another local
recurrence was found in a patient who underwent
bilobectomy. However, the difference in recurrence
rate was not statistically significant between patients
with standard resection and those with sublobar resec-
tion in our study. The patients who underwent sublobar
resection usually had poor cardiopulmonary function
or other comorbidity. These patients might die from
diseases other than lung cancer, and this could con-
tribute to a worse outcome. Therefore, unfitness for
standard resection might be alternatively used as a
predictor for poor overall survival.
The number of mediastinal lymph nodes dissected
during thoracotomy could reflect the quality of lymph-
adenectomy in patients with resected stage I NSCLC.
Better quality of lymphadenectomy might lead to more
accurate tumor staging and therefore influence sur-
vival.29 In our previous study of prognostic factors for
resected stage I NSCLC with diameter ≤ 3 cm, pa-
tients with ≤ 15 mediastinal lymph nodes dissected had
worse survival outcome than those with > 15.30 In the
current study, univariate analysis revealed a similar out-
come in patients with NSCLC with a diameter ≤ 1 cm
with regard to the number of mediastinal lymph nodes
dissected. However, it was not a significant predictor
in multivariate analysis.
There were several limitations in our study. This
was a surgical series of patients with NSCLC with a
diameter ≤ 1 cm. Some patients with such tumors diag-
nosed with advanced disease or distant metastasis might
not be surgical candidates. Therefore, long-term sur-
vival could not be applied to all NSCLC with a diam-
eter ≤ 1 cm at diagnosis. Furthermore, the sample size
in our study was not very large. Multicenter, prospec-
tive randomized trials are required to compare the
benefits and drawbacks between sublobar resection
and lobectomy.
In conclusion, most patients with NSCLC ≤ 1 cm
in diameter had stage I disease. Long-term survival was
good. Sublobar resection, performed in patients unfit
for standard resection, is a poor prognostic factor for
overall survival.
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